First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial - PubMed
3 hours ago
- #immunotherapy
- #nasopharyngeal cancer
- #clinical trial
- First-line tislelizumab plus chemotherapy showed improved progression-free survival (PFS) vs. placebo plus chemotherapy in recurrent or metastatic nasopharyngeal cancer (NPC).
- Median PFS was 9.6 months for tislelizumab vs. 7.4 months for placebo (HR 0.53).
- Median overall survival (OS) was 45.3 months for tislelizumab vs. 31.8 months for placebo (HR 0.73).
- Greater OS benefit was observed in participants with high B-cell gene expression (HR 0.41).
- Treatment-emergent adverse events were common but manageable, with higher immune-mediated events in the tislelizumab group.
- The study supports tislelizumab plus chemotherapy as a viable first-line treatment for recurrent or metastatic NPC.